AMENDMENTS TO THE CLAIMS

Listing of Claims:

Claims 1-19 (canceled)

Claim 20 (currently amended): A combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors, and S-adenosylmethionine decarboxylase inhibitors and (c) an epothilone which is epothilone B, ~~derivative of formula I~~



~~(I)~~

~~wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O,~~

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 21 (previously presented): Combination according to claim 20 wherein the HER-1 or HER-2 antibody is trastuzumab.

Claim 22 (previously presented): Combination according to claim 20 wherein the antineoplastic agent is a topoisomerase I inhibitor.

Claim 23 (previously presented): Combination according to claim 20 wherein the antineoplastic agent is a topoisomerase II inhibitor.

Claim 24 (previously presented): Combination according to claim 20 wherein the antineoplastic agent is an aromatase inhibitor.

Claim 25 (previously presented): Combination according to claim 20 wherein the antineoplastic agent is a microtubule active agent.

Claim 26 (cancelled)

Claim 27 (previously presented): Combination according to claim 20 which is a combined preparation

Claim 28 (currently amended): A combination which comprises
(a) a HER-1 or a HER-2 antibody and
(b) an epothilone which is epothilone B, ~~derivative of formula I~~



~~(I)~~

~~wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl and Z is O,~~
in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 29 (previously presented): Combination according to claim 28 wherein the HER-1 or HER-2 antibody is trastuzumab.

Claim 30 (cancelled)

Claim 31 (previously presented) Combination according to claim 28 which is a combined preparation.

Claim 32 (currently amended): A combination which comprises (a) at least one antineoplastic agent selected from the group consisting of topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors, and S-adenosylmethionine decarboxylase inhibitors and (b) an epothilone which is epothilone B, ~~derivative of formula I~~



~~(I)~~

~~wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O,~~

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 33 (previously presented): Combination according to claim 32 wherein the antineoplastic agent is a topoisomerase I inhibitor.

Claim 34 (previously presented): Combination according to claim 32 wherein the antineoplastic agent is a topoisomerase II inhibitor.

Claim 35 (previously presented): Combination according to claim 32 wherein the antineoplastic agent is a microtubule active agent.

Claim 36 (cancelled)

Claim 37 (previously presented): Combination according to claim 32 which is a combined preparation

Claim 38 (currently amended): A combination which comprises (a) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors and antiestrogens and (b) an epothilone which is epothilone B, ~~derivative of formula I~~



~~(I)~~

~~wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O,~~

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 39 (previously presented): Combination according to claim 38 wherein the antineoplastic agent is an aromatase inhibitor.

Claim 40 (cancelled

Claim 41 (previously presented): Combination according to claim 38 which is a combined preparation.

Claim 42 (cancelled)

Claim 43 (previously presented): Method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination according to claim 20 in a quantity which is jointly therapeutically effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 44 (previously presented): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 20 and at least one pharmaceutically acceptable carrier.

Claim 45 (previously presented): A combination according to claim 20 for use in the treatment of a proliferative disease.

Claims 46-49 (cancelled)

Claim 50 (currently amended): A commercial package comprising (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors, and S-adenosylmethionine decarboxylase inhibitors and (c) an epothilone which is epothilone B, ~~derivative of formula I~~



~~(I)~~

~~wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O,~~

together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.